resveratrol has been researched along with Alzheimer Disease in 185 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (7.57) | 29.6817 |
| 2010's | 115 (62.16) | 24.3611 |
| 2020's | 56 (30.27) | 2.80 |
| Authors | Studies |
|---|---|
| Krisa, S; Mérillon, JM; Monti, JP; Quentin, L; Richard, T; Rivière, C | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Dong, Y; Flaherty, DP; Ikezu, T; Kiyota, T; Vennerstrom, JL | 1 |
| Iglésias, ML; Krisa, S; Mérillon, JM; Monti, JP; Nassra, M; Papastamoulis, Y; Poupard, P; Richard, T; Waffo-Teguo, P | 1 |
| Guo, Y; Li, J; Li, X; Liao, Q; Lu, C; Xie, Z; Yao, M | 1 |
| Guo, Y; Huang, L; Li, X; Lu, C; Luo, HB; Luo, Z; Yan, J; Yan, M | 1 |
| Kong, LY; Li, SY; Wang, XB | 1 |
| Kong, LY; Li, SY; Wang, XB; Xie, SS; Xu, ZC; Yu, WY | 1 |
| Bag, S; Cho, H; LeVine, H; Redjeb, H; Sood, A; Török, B; Török, M; Tulsan, R; Zhou, W | 1 |
| Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Xie, SS | 1 |
| Huang, L; Li, W; Li, X; Wang, B; Wang, Y; Wang, Z | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Alcendor, R; Martínez, A; McCurdy, R; Podgorny, M; Rahman, T; Sanogo, I | 1 |
| Kong, LY; Li, F; Li, XM; Wang, J; Wang, XB; Wang, ZM; Wu, JJ | 1 |
| Dey, S; Kumar, R; Nigam, L; Singh, AP; Singh, K; Subbarao, N | 1 |
| Horton, W; Kugyela, N; Kulkarni, A; LeVine, H; Peerannawar, S; Sood, A; Soule, J; Török, B; Török, M; Tran, CD; Tulsan, R | 1 |
| Ma, Y; Sheng, R; Xu, P; Zhang, M | 1 |
| Bartolini, M; Bolognesi, ML; Guidotti, L; Hrabinova, M; Jeřábek, J; Korábečný, J; Kuča, K; Monti, B; Peña-Altamira, LE; Petralla, S; Roberti, M; Sepsova, V; Soukup, O; Uliassi, E | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Chen, Y; Li, Q; Sun, H; Yang, H | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL | 1 |
| Cai, P; Kong, LY; Li, F; Wang, J; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Cai, P; Fang, SQ; Kong, LY; Liu, QH; Tang, YW; Wang, C; Wang, XB; Yang, HL; Yang, XL | 1 |
| Chan, ASC; Feng, X; Hu, J; Huang, L; Li, X; Wang, Z; Yang, X | 1 |
| Cheng, B; Fang, Y; Gu, Q; Hua, P; Xia, W; Xu, J; Zhou, H | 1 |
| Chen, L; Feng, F; Liao, Q; Liu, W; Qu, W; Sun, H; Xu, J; Ye, F; Zhang, W; Zhao, Y | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Cai, P; Fang, SQ; Kong, LY; Liu, QH; Wang, XB; Yang, HL; Yang, XL | 1 |
| Chen, J; Cheng, G; Ma, Y; Sheng, R; Xu, P; Zhang, M | 1 |
| Cai, P; Kong, LY; Liu, QH; Shi, CJ; Tang, YW; Wang, XB; Yang, HL; Yang, XL | 1 |
| Fang, Y; Gu, Q; Xu, J; Zhou, H | 1 |
| Chen, S; Han, J; Li, Z; Liu, T; Wang, M; Wu, M | 1 |
| Du, H; Jiang, X; Liu, S; Ma, F; Ma, M; Xu, H | 1 |
| Albuquerque, HMT; Malafaia, D; Silva, AMS | 1 |
| Chowdhury, SR; Fu, L; Gu, J; Hu, Y; Jiang, F; Lam, C; Lei, S; Lu, D; Tavallaie, MS; Wang, J | 1 |
| Chen, S; Du, J; Li, R; Li, Z; Liu, T; Xing, S | 1 |
| Calazans, MO; De Oliveira, ACP; Ribeiro, R; Santos, AC; Vieira, LB | 1 |
| Du, F; Jiao, J; Li, C; Yang, Y; Yao, M; Zhao, H | 1 |
| Brothers, SP; Dennison, JL; Gravel, E; Hammond-Vignini, S; Hayward, MA; Ke, D; Li, Z; Lohse, I; Modarresi, F; Timmons, JA; Volmar, CH; Wahlestedt, C; Wang, J | 1 |
| Abozaid, OAR; Ahmed, ESA; Aziza, S; El-Sonbaty, S; Emad, B; Sallam, MW | 1 |
| Caramelli, P; Fontes, AFDS; Gomes, KB; Tosatti, JAG | 1 |
| Fang, X; Wang, L; Zhang, J; Zhao, J | 1 |
| Akhtar, MF; Akter, A; Hussein Sweilam, S; Islam, F; Islam, MR; Md Ashraf, G; Nafady, MH; Or-Rashid, MH; Perveen, A; Rahman, MH; Rashid, S; Saha, S | 1 |
| Chen, L; Li, Q; Li, X; Tian, B | 1 |
| Ergüzel, TT; Karahan, M; Kocatürk, RR; Konuk, M; Özcan, ÖÖ; Tarhan, N; Temizyürek, A | 1 |
| Albasanz, JL; Griñán-Ferré, C; Izquierdo-Ramírez, PJ; Martín, M; Pallàs, M; Sánchez-Melgar, A | 1 |
| Chen, X; El-Kott, AF; Elsaid, FG; Ghanem, RA; Salem, ET; Xu, Z; Xue, J; Zhang, M | 1 |
| AbdulWahab, A; Ayo, JO; Danjuma, NM; Isa, AS; Muhammad, MS; Umar, AH | 1 |
| Abe, K; Bian, Z; Feng, T; Hu, X; Morihara, R; Tadokoro, K; Yamashita, T; Yu, H | 1 |
| Barić, D; Fodor, L; Horváth, O; Lasić, Z; Lovrić, MJ; Marinić, Ž; Milašinović, V; Mlakić, M; Molčanov, K; Odak, I; Škorić, I | 1 |
| Anusuyadevi, M; Jayachandran, KS; Kandasamy, M; Manickam, N; Surya, K | 1 |
| A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X | 1 |
| Tang, Z; Zhang, M | 1 |
| Li, Z; Mei, J; Wang, Y; Wu, X; Yang, L; Zheng, G | 1 |
| Huo, X; Liu, H; Wang, S; Yin, S; Yin, Z | 1 |
| Bahrehmand, F; Fakhri, S; Gholami, M; Jalili, C; Kakebaraei, S; Kakehbaraei, S; Kiani, A | 1 |
| Hassan, MI; Islam, A; Khan, S; Shahid, M | 1 |
| Li, Z; Mei, J; Wang, Y; Yang, L; Zheng, G | 1 |
| Cao, LH; Chen, F; Hao, Y; Hou, J; Liu, J; Ma, Y; Ping, Y; Shao, L; Xu, C; Zhang, Y | 1 |
| Cao, D; Chen, Y; Guo, J; Jia, Z; Liang, B; Liu, J; Lu, S; Tang, R; Yang, Y; Yuan, X; Zhu, H | 1 |
| Báo, SN; Cazarin, CA; Chorilli, M; da Rocha, MCO; da Silva, PB; De-Souza, MM; Dos Santos, KP; Fonseca-Santos, B | 1 |
| Kusaka, K; Yokoyama, T | 1 |
| Fan, X; Song, M; Tu, W | 1 |
| Bernards, MT; Guan, YX; Han, YL; He, Y; Xiao, C; Yin, HH | 1 |
| Ganaraja, B; Joy, T; Murlimanju, BV; Pai, MM; Rao, YL; Ullal, SD | 1 |
| Chen, JY; Lu, JH; OuYang, D; Zhang, S; Zhu, Q | 1 |
| Choi, I; Danish Rizvi, SM; Farhana, A; Hussain, T; Nazam, N; Shaikh, S | 1 |
| Ding, Y; Kong, D; Xie, Y; Yan, Y; Yang, H; Yu, H | 1 |
| Chu, X; Cui, L; Fu, S; Gao, C; Han, Y; Li, Y; Sun, B | 1 |
| Domanowska, A; Malinowski, B; Wiciński, M; Wódkiewicz, E | 1 |
| Albasanz, JL; Martín, M; Pallàs, M; Sánchez-Melgar, A | 1 |
| Al-Edresi, S; Alsalahat, I; Aojula, H; Freeman, S; Penny, J | 1 |
| MagalhÃes, GJP; Santana, ACF; Sousa, JCE | 1 |
| Albasanz, JL; Griñán-Ferré, C; Martín, M; Pallàs, M; Sánchez-Melgar, A | 1 |
| Castro, NG; Dardenne, LE; de Azevedo, LL; de Freitas Silva, M; Fonseca Nadur, N; Gontijo, VS; Guedes, IA; Guimarães, MJR; Kümmerle, AE; M R da Silva, F; Pruccoli, L; Tardelli Lima, E; Tarozzi, A; Viegas, C | 1 |
| Cao, D; Jiang, D; Li, J; Yu, H; Zhou, D | 1 |
| Komorowska, J; Szukiewicz, D; Wątroba, M | 1 |
| Baier, CJ; Biscussi, B; Mañez, PA; Murray, AP; Richmond, V | 1 |
| Al-Nakkash, L; Anderson, M; Babu, JR; Broderick, TL; Geetha, T; Li, R; Plochocki, JH; Rasool, S; Zhang, Y | 1 |
| Huang, J; Huang, N; Jin, F; Jin, H; Li, Y; Luo, Y; Shi, J; Xu, S; Yu, C | 1 |
| Bahar, B; Singhrao, SK | 1 |
| Corpas, R; Gatius, A; Griñán-Ferré, C; Pallàs, M; Rodríguez-Farré, E; Sanfeliu, C; Sarroca, S; Vilchez, D | 1 |
| Alghamdi, BS; Alshehri, FS; Kurdi, M; Labban, S | 1 |
| Fang, Y; Li, J; Liu, Y; Si, W; Su, Z; Zeng, P | 1 |
| Andres-Lacueva, C; Bellver-Sanchis, A; Chillón, M; Corpas, R; Griñán-Ferré, C; Izquierdo, V; Pallàs, M; Roig-Soriano, J; Sanfeliu, C; Somogyvári, M; Sőti, C | 1 |
| Bren, U; Furlan, V | 1 |
| Choi, B; Jang, BG; Kim, MJ; Koh, YH; Lee, J | 1 |
| Bagit, A; MacPherson, REK; Yang, AJT | 1 |
| Naina-Mohamed, I; Qodriyah, HMS; Syarifah-Noratiqah, SB; Zulfarina, MS | 1 |
| Jiaranaikulwanitch, J; Kimura, S; Kitphati, W; Nukoolkarn, V; Pratuangdejkul, J; Puksasook, T; Saito, N; Suwanborirux, K; Tadtong, S | 1 |
| Cao, Y; Li, M; Li, MZ; Liu, BJ; Shi, FX; Sun, DS; Tian, Q; Wang, JZ; Wang, L; Xu, WQ; Zhou, XW | 1 |
| Moussa, C; Sawda, C; Turner, RS | 1 |
| Chen, N; Kou, X | 1 |
| Cheng, YC; Chiang, MC; Nicol, CJ | 1 |
| Jia, Y; Liu, X; Wang, N | 1 |
| Ehninger, D; Hettich, MM; Kickstein, E; Krauß, S; Matthes, F; Pfurtscheller, S; Posey, K; Schneider, R; Schweiger, S; Weber, S | 1 |
| Guan, F; Huang, T; Li, Q; Ma, S; Meng, N; Wang, J; Wang, X; Wu, J; Xing, Q; Xu, L; Yang, B; Yang, GL; Zhang, K; Zhang, T; Zhang, Y | 1 |
| Lange, KW; Li, S | 1 |
| Anusuyadevi, M; Essa, MM; Gobinath, T; Jayachandran, KS; Kandasamy, M; Mohan, S; Nisha, M; Salomy, A | 1 |
| Chen, ZJ; Yang, DH; Yang, YF; Zhang, YT | 1 |
| Allam, A; Bariya, A; Butani, SB; Othman, S; Rajput, A | 1 |
| Hayakari, R; Imaizumi, T; Kawaguchi, S; Kimoto, T; Matsumiya, T; Seino, S; Seya, K; Tanaka, H; Tanji, K; Tsuruga, K; Yoshida, H | 1 |
| Corpas, R; Griñán-Ferré, C; Pallàs, M; Rodríguez-Farré, E; Sanfeliu, C | 1 |
| Kulashekar, M; Peuler, JD; Stom, SM | 1 |
| Chu, D; Dai, W; Gu, J; Huang, Q; Jin, N; Liu, F; Qian, S; Qian, W | 1 |
| Chomentowski, A; Drygalski, K; Fereniec, E; Kiełczewska, A; Koryciński, K; Modzelewska, B; Odrzygóźdź, C | 1 |
| Chen, J; Wang, N; Wang, W; Yang, L; Zheng, G | 1 |
| Dos Santos, SM; Gomes, BAQ; Gonçalves, PR; Mendes, PFS; Monteiro, MC; Rodrigues, CA; Romeiro, CFR; Sakai, JT; Silva, JPB; Varela, ELP | 1 |
| Goyal, B; Goyal, D; Saini, RK; Shuaib, S | 1 |
| Liu, J; Liu, Y; Sun, J; Wei, C; Xie, W; Xu, M; Zhou, H | 1 |
| Deora, GS; Li, QS; Li, Y; Ruan, BF | 1 |
| Al-Nakkash, L; Alkhouli, MF; Anderson, M; Babu, JR; Broderick, TL; Castro, M; Hung, J; Plochocki, JH; Squire, M | 1 |
| Li, X; Liu, X; Ma, X; Tan, Y; Wu, J; Xie, J; Zhao, Y; Zhou, Y | 1 |
| Chen, Y; Liang, ZM; Peng, L; Sheng, SY; Shi, GW; Shi, YS; Wang, F; Wang, YP; Zhang, XM | 1 |
| Ding, Y; He, XY; He, Y; Kong, D; Liang, B; Wang, J; Yan, Y; Yang, H; Yu, H | 1 |
| Abou-Taleb, HA; Kharshoum, RM; Naguib, DM; Salem, HF | 1 |
| Dong, R; Li, J; Yang, Q; Zhang, L; Zhang, Y; Zhao, H | 1 |
| Agapouda, A; Eckert, A; Grimm, A; Lejri, I | 1 |
| Diniz, BS; Leszek, J; Szczechowiak, K | 1 |
| Alquézar, C; Arumí-Planas, M; Cosín-Tomàs, M; Kaliman, P; Martín-Requero, Á; Pallàs, M; Sanfeliu, C; Senserrich, J; Suñol, C | 1 |
| Bao, L; Dong, H; Feng, X; Gao, Q; Gao, Y; Hao, J; Liang, N; Liu, H; Peng, L; Sun, J; Yu, X; Yue, Q; Zhang, J; Zhu, D | 1 |
| Bradford, KL; Sikalidis, AK; Varamini, B | 1 |
| Resurreccion, AV; Sales, JM | 1 |
| Bisoffi, M; Brady, CI; Brown, DC; Chamberlin, R; Deck, LM; Garwood, M; Heidrich, JE; Severns, V; Sillerud, LO; Solberg, NO; Vander Jagt, DL; Vander Jagt, TA; Vigil, JR | 1 |
| Cai, L; Chen, GR; Deng, Q; He, XP; Li, J; Tian, H; Wang, CZ; Zang, Y | 1 |
| Huang, L; Jia, X; Li, J; Li, X; Mao, F; Miao, H; Sun, Y; Yan, J | 1 |
| Bigford, GE; Del Rossi, G | 1 |
| Camins, A; Del Valle, J; Ferrer, I; Griñán-Ferré, C; Pallàs, M; Porquet, D; Sanfeliu, C | 1 |
| Devi, KP; Malar, DS | 1 |
| Dubner, L; Ho, L; Pasinetti, GM; Wang, J; Zhao, W | 1 |
| Bayan, Y; El-Sayed, NS | 1 |
| Ma, T; Tan, L; Tan, MS; Yu, JT | 1 |
| Bredesen, DE; Fiala, M; Halder, RC; Porter, V; Ross, O; Sagong, B; Sayre, J | 1 |
| Dußling, LM; Fitzenberger, E; Mahn, FL; Regitz, C; Wenzel, U | 1 |
| Alexi, X; Alexis, MN; Belda, O; Csonka, R; Dellis, D; Hamelink, E; Koukoulitsa, C; Leonis, G; Mavromoustakos, T; Micha-Screttas, M; Papadopoulos, MG; Steele, BR; Villalonga-Barber, C | 1 |
| Ficarra, S; Galtieri, A; Giardina, B; Russo, A; Tellone, E | 1 |
| Aisen, PS; Brewer, JB; Craft, S; Mintzer, J; Raman, R; Reynolds, BA; Rissman, RA; Thomas, RG; Turner, RS; van Dyck, CH | 1 |
| Cheng, XJ; Li, N; Li, XM; Liu, TT; Wang, Q; Zhao, HF | 1 |
| Cheng, X; Li, N; Wang, Q; Zhao, H | 1 |
| Gyengesi, E; Münch, G; Sharman, MJ; Sonego, S; Venigalla, M | 1 |
| Chang, SS; Chang, WC; Chen, HI; Chi, TC; Chu, KH; Ko, HA; Ko, SY; Shieh, TM | 1 |
| Braidy, N; Grant, R; Jayasena, T; Jugder, BE; Mansour, H; Nabavi, SM; Poljak, A; Sachdev, P | 1 |
| Chen, J; Chen, L; Cheng, R; Feng, X; O'Donnell, JM; Pan, X; Wang, G; Wang, L; Wang, W; Wu, F; Xu, Y; Yu, Y; Zhang, HT | 1 |
| Ahmed, T; Braidy, N; Javed, S; Nabavi, SF; Nabavi, SM; Šamec, D; Tariq, A; Tejada, S | 1 |
| Giacomini, E; Guidotti, L; Recanatini, M; Roberti, M; Rupiani, S | 1 |
| Libert, C; Van Cauwenberghe, C; Vandenbroucke, RE; Vandendriessche, C | 1 |
| Erdogan, CS; Vang, O | 1 |
| Dong, W; Wang, R | 1 |
| Dance, A | 1 |
| Madi, S; Sillerud, LO; Tafoya, MA | 1 |
| Ahn, J; Aisen, PS; Hebron, M; Huang, X; Moussa, C; Rissman, RA; Turner, RS | 1 |
| Wightman, EL | 1 |
| Martin, I | 1 |
| Andrade, S; Coelho, MA; Duarte, A; Fenart, L; Gosselet, F; Loureiro, JA; Neves, AR; Nunes, C; Pereira, MC; Queiroz, JF; Sevin, E | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Pezzuto, JM | 1 |
| Beal, MF; Chen, HL; Gibson, GE; Karuppagounder, SS; Pinto, JT; Xu, H | 1 |
| Davies, P; Dreses-Werringloer, U; Marambaud, P; Vingtdeux, V; Zhao, H | 1 |
| Fivecoat, H; Ho, L; Ling, E; Pan, Y; Pasinetti, GM; Wang, J | 1 |
| Kim, J; Lee, HJ; Lee, KW | 1 |
| Chandakkar, P; Davies, P; Ferruzzi, MG; Giliberto, L; Janle, EM; Lobo, J; Marambaud, P; Simon, JE; Vingtdeux, V; Wu, Q; Zhao, H | 1 |
| Iglésias, ML; Mérillon, JM; Monti, JP; Pawlus, AD; Pedrot, E; Richard, T; Waffo-Teguo, P | 1 |
| Huber, K; Superti-Furga, G | 1 |
| Granzotto, A; Zatta, P | 1 |
| Camins, A; Casadesus, G; Chang, J; Joseph, JA; Pallas, M; Porquet, D; Reeves, J; Rimando, A; Shukitt-Hale, B; Smith, MA | 1 |
| Al-Abed, Y; Capiralla, H; Davies, P; Marambaud, P; Sankowski, R; Vingtdeux, V; Zhao, H | 1 |
| Gray, SG | 1 |
| Dong, H; Gong, Q; Li, F; Shi, J | 1 |
| Bracale, R; Davinelli, S; Intrieri, M; Sapere, N; Scapagnini, G; Zella, D | 1 |
| Maag, JL; Musgrave, IF; Smid, SD | 1 |
| Kermode, AR; Zeng, Y; Zhao, T | 1 |
| Cardoso, I; Ribeiro, CA; Saraiva, MJ | 1 |
| Chen, L; Fuchs, PM; Kanazirska, MV; Lal, S; Vassilev, PM; Verma, J | 1 |
| Bayod, S; Camins, A; Canudas, AM; Casadesús, G; del Valle, J; Pallàs, M; Pelegrí, C; Porquet, D; Sanfeliu, C; Vicente, A; Vilaplana, J | 1 |
| Chen, CP; Chen, YJ; Villaflores, OB; Wu, TY; Yeh, JM | 1 |
| Davies, P; Marambaud, P; Zhao, H | 1 |
| Chen, J; Chen, LF; Gan, L; Kwon, H; Mucke, L; Mueller-Steiner, S; Yi, S; Zhou, Y | 1 |
| Anekonda, TS | 1 |
| Ramassamy, C | 1 |
| Huang, YM; Luo, L | 1 |
| Bogdanovic, N; Jefremov, V; Karelson, E; Zilmer, K; Zilmer, M | 1 |
| Armour, SM; Baur, JA; Delalle, I; Dobbin, MM; Fischer, A; Kim, D; Nguyen, MD; Puigserver, P; Rodgers, JT; Sananbenesi, F; Sinclair, DA; Sui, G; Tsai, LH | 1 |
| Bates, TE; Butterfield, DA; Calabrese, V; Calafato, S; Cornelius, C; De Lorenzo, A; Dinkova Kostova, AT; Mancuso, C | 1 |
| Baxter, RA | 1 |
61 review(s) available for resveratrol and Alzheimer Disease
| Article | Year |
|---|---|
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans | 2017 |
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Curcumin; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Structure-Activity Relationship; Tacrine; tau Proteins | 2021 |
Is resveratrol a prospective therapeutic strategy in the co-association of glucose metabolism disorders and neurodegenerative diseases?
Topics: Alzheimer Disease; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Humans; Neurodegenerative Diseases; Resveratrol | 2022 |
Effects of Resveratrol Supplementation on the Cognitive Function of Patients with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials.
Topics: Activities of Daily Living; Alzheimer Disease; Cognition; Dietary Supplements; Glucose; Humans; Randomized Controlled Trials as Topic; Resveratrol | 2022 |
Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Humans; Neuroprotection; Neuroprotective Agents; Resveratrol; Sirtuin 1 | 2022 |
Effect of nutritional supports on malnutrition, cognition, function and biomarkers of Alzheimer's disease: a systematic review.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Biomarkers; Cognition; Dietary Supplements; Humans; Malnutrition; Nutritional Support; Quality of Life; Resveratrol; Vitamin D | 2023 |
Resveratrol Mediated Regulation of Hippocampal Neuroregenerative Plasticity via SIRT1 Pathway in Synergy with Wnt Signaling: Neurotherapeutic Implications to Mitigate Memory Loss in Alzheimer's Disease.
Topics: Alzheimer Disease; Amnesia; Hippocampus; Humans; Neurogenesis; Resveratrol; Sirtuin 1; Wnt Signaling Pathway | 2023 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
Therapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation.
Topics: Alzheimer Disease; Humans; Memory Disorders; Neurodegenerative Diseases; Resveratrol; Sirtuin 1 | 2023 |
Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain; Nanoparticles; Resveratrol | 2023 |
Nature's toolbox against tau aggregation: An updated review of current research.
Topics: Alzheimer Disease; Humans; Neurodegenerative Diseases; Resveratrol; tau Proteins | 2023 |
Does resveratrol improve cognition in humans? A scientometric study to an in-depth review.
Topics: Affect; Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Female; Humans; Infant, Newborn; Resveratrol; Young Adult | 2023 |
Neuroprotective effects of resveratrol in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Neuroprotection; Resveratrol | 2020 |
Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Neuroprotective Agents; Resveratrol; tau Proteins | 2019 |
Anti-Amyloid Aggregating Gold Nanoparticles: Can they Really be Translated from Bench to Bedside for Alzheimer's Disease Treatment?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Blood-Brain Barrier; Brain; Catechin; Gene Expression Regulation; Gold; Humans; Metal Nanoparticles; Molecular Targeted Therapy; Neuroprotective Agents; Protein Aggregates; Resveratrol; Translational Research, Biomedical | 2020 |
Research Progress on Alzheimer's Disease and Resveratrol.
Topics: Alzheimer Disease; Animals; Antioxidants; Biomedical Research; Humans; Receptors, AMPA; Resveratrol; Synapses | 2020 |
Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential.
Topics: Alzheimer Disease; Antioxidants; Cognition; Humans; Resveratrol | 2020 |
Review of beneficial effects of resveratrol in neurodegenerative diseases such as Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Resveratrol | 2020 |
Signaling mechanisms underlying inhibition of neuroinflammation by resveratrol in neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Inflammation; Macrophages; Mice; Microglia; Neurodegenerative Diseases; Neurons; Parkinson Disease; Rats; Resveratrol; Signal Transduction | 2021 |
The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: From antioxidant to epigenetic therapy.
Topics: Aged; Alzheimer Disease; Antioxidants; Cognitive Dysfunction; Epigenesis, Genetic; Humans; Neuroprotective Agents; Oxidative Stress; Resveratrol | 2021 |
Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurogenerative Disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Humans; Neuronal Plasticity; Resveratrol | 2021 |
Natural Polyphenols in the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Catechin; Curcumin; Disease Progression; Humans; Neuroprotective Agents; Oxidative Stress; Polyphenols; Resveratrol | 2018 |
Resveratrol for Alzheimer's disease.
Topics: Alzheimer Disease; Blood-Brain Barrier; Double-Blind Method; Humans; Resveratrol; Sirtuins; Stilbenes; Treatment Outcome | 2017 |
Resveratrol as a Natural Autophagy Regulator for Prevention and Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Autophagy; Brain; Cognition; Humans; Inflammation Mediators; MicroRNAs; Neuroprotective Agents; Resveratrol; Signal Transduction; Stilbenes | 2017 |
Resveratrol and Amyloid-Beta: Mechanistic Insights.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Humans; Neurons; Resveratrol; Stilbenes | 2017 |
Resveratrol, pterostilbene, and dementia.
Topics: Alzheimer Disease; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Brain; Clinical Trials as Topic; Cognitive Dysfunction; Dementia; Disease Models, Animal; Humans; Maze Learning; Neuroprotective Agents; Resveratrol; Stilbenes | 2018 |
Biophysical interaction of resveratrol with sirtuin pathway: Significance in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Homeostasis; Humans; Neuroprotective Agents; Resveratrol; Signal Transduction; Sirtuin 1 | 2018 |
Resveratrol's Potential in the Adjunctive Management of Cardiovascular Disease, Obesity, Diabetes, Alzheimer Disease, and Cancer.
Topics: Alzheimer Disease; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus; Humans; Obesity; Resveratrol | 2018 |
Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Caloric Restriction; Clinical Trials as Topic; Glycation End Products, Advanced; Humans; Nerve Degeneration; Oxidative Stress; Reactive Oxygen Species; Resveratrol; Sirtuins | 2018 |
Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Neuroprotective Agents; Resveratrol; Sirtuin 1 | 2018 |
Derivatives and Analogues of Resveratrol: Recent Advances in Structural Modification.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Free Radicals; Humans; Molecular Structure; Neoplasms; Resveratrol | 2019 |
Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence.
Topics: Alzheimer Disease; Animals; Antioxidants; Clinical Trials as Topic; Cognitive Dysfunction; Drug Evaluation, Preclinical; Energy Metabolism; Evidence-Based Medicine; Ginkgo biloba; Humans; Mitochondria; Oxidative Stress; Phytoestrogens; Plant Extracts; Pregnanolone; Resveratrol | 2019 |
Diet and Alzheimer's dementia - Nutritional approach to modulate inflammation.
Topics: Alzheimer Disease; Butyrates; Caffeine; Cholecalciferol; Curcumin; Diet; Dietary Supplements; Encephalitis; Fatty Acids; Fatty Acids, Omega-3; Gastrointestinal Microbiome; Glycation End Products, Advanced; Humans; Meat; Resveratrol; Vitamin B Complex | 2019 |
Resveratrol in peanuts.
Topics: Alzheimer Disease; Antioxidants; Arachis; Biological Availability; Cardiovascular Diseases; Diet; Humans; Neoplasms; Resveratrol; Stilbenes | 2014 |
Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.
Topics: Acetylcarnitine; Alzheimer Disease; Brain; Brain Injuries; Cinnamates; Cognition Disorders; Curcumin; Depsides; Diet; Dietary Supplements; Fatty Acids, Omega-3; Humans; Neurodegenerative Diseases; Oxidative Stress; Polyphenols; Resveratrol; Rosmarinic Acid; Stilbenes | 2014 |
Dietary polyphenols for treatment of Alzheimer's disease--future research and development.
Topics: Alzheimer Disease; Animals; Coumaric Acids; Curcumin; Diet; Flavonoids; Humans; Research; Resveratrol; Stilbenes | 2014 |
Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment.
Topics: Alzheimer Disease; Amyloid; Animals; Humans; Polyphenols; Resveratrol; Stilbenes; Vitis | 2015 |
Resveratrol as a therapeutic agent for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Neuroprotective Agents; Oxidative Stress; Resveratrol; Stilbenes | 2014 |
Resveratrol: A Focus on Several Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Humans; Huntington Disease; Mitochondria; Neurodegenerative Diseases; Oxidative Stress; Parkinson Disease; Resveratrol; Stilbenes | 2015 |
Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Biological Products; Chronic Disease; Curcumin; Fish Oils; Humans; Inflammation; Neurodegenerative Diseases; Neurofibrillary Tangles; Neuroprotective Agents; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes | 2016 |
Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Humans; Neuroprotective Agents; Resveratrol; Stilbenes | 2016 |
Resveratrol and Alzheimer's Disease: Mechanistic Insights.
Topics: Alzheimer Disease; Animals; Autophagy; Humans; Mitochondria; Nerve Degeneration; Oxidative Stress; Resveratrol; Stilbenes | 2017 |
The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design.
Topics: Alzheimer Disease; Antineoplastic Agents, Phytogenic; Bibenzyls; Chemistry, Pharmaceutical; Drug Design; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship | 2016 |
Caloric restriction: beneficial effects on brain aging and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Biomimetics; Brain; Caloric Restriction; Energy Metabolism; Humans; Resveratrol; Sirolimus; Stilbenes | 2016 |
Challenges in Analyzing the Biological Effects of Resveratrol.
Topics: Alzheimer Disease; Animals; Antioxidants; Biological Availability; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Humans; Metabolic Diseases; Neoplasms; Phytochemicals; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes | 2016 |
[Effects of resveratrol-induced cellular autophagy in control of neurodegenerative diseases].
Topics: Alzheimer Disease; Autophagy; Humans; Huntington Disease; Neurodegenerative Diseases; Parkinson Disease; Resveratrol; Stilbenes | 2016 |
Potential benefits of phytochemicals against Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes | 2017 |
Therapeutic potential of resveratrol in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Dementia; Flavonoids; Humans; Nerve Degeneration; Phenols; Polyphenols; Resveratrol; Stilbenes; Wine | 2008 |
The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Caloric Restriction; Humans; Longevity; NAD; Resveratrol; Sirtuin 1; Stilbenes | 2010 |
Naturally occurring phytochemicals for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Catechin; Cognition Disorders; Curcumin; Dietary Supplements; Humans; Oxidative Stress; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes | 2010 |
Neuroprotective properties of resveratrol and derivatives.
Topics: Alzheimer Disease; Animals; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Resveratrol; Stilbenes | 2011 |
After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
Topics: Alzheimer Disease; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Neurodegenerative Diseases; Parkinson Disease; Resveratrol; Sirtuins; Stilbenes; Up-Regulation | 2011 |
Epigenetic treatment of neurological disease.
Topics: Alzheimer Disease; Butylamines; Cell Differentiation; Endoplasmic Reticulum Stress; Epigenesis, Genetic; Histone Code; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Huntington Disease; Hydroxamic Acids; Neurons; Phenylbutyrates; Protein Processing, Post-Translational; Resveratrol; Stilbenes; Valproic Acid; Vorinostat | 2011 |
Resveratrol, a neuroprotective supplement for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Humans; Neurons; Neuroprotective Agents; Resveratrol; Stilbenes | 2012 |
Pleiotropic protective effects of phytochemicals in Alzheimer's disease.
Topics: Alzheimer Disease; Catechin; Curcumin; Humans; Neuroprotective Agents; NF-E2-Related Factor 2; Polyphenols; Resveratrol; Stilbenes | 2012 |
Dietary polyphenol-derived protection against neurotoxic β-amyloid protein: from molecular to clinical.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Catechin; Cell Line; Curcumin; Diet; Humans; Models, Molecular; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Plants; Polyphenols; Resveratrol; Stilbenes; Tea | 2012 |
Curcuminoids and resveratrol as anti-Alzheimer agents.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antioxidants; Curcumin; Diarylheptanoids; Humans; Male; Resveratrol; Stilbenes; tau Proteins | 2012 |
Resveratrol--a boon for treating Alzheimer's disease?
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Caloric Restriction; Humans; Nerve Degeneration; Reactive Oxygen Species; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes | 2006 |
Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Blueberry Plants; Clinical Trials as Topic; Cognition; Curcumin; Flavonoids; Ginkgo biloba; Humans; Neurodegenerative Diseases; Parkinson Disease; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Resveratrol; Signal Transduction; Stilbenes; Tea; Wine | 2006 |
Natural antioxidants in Alzheimer's disease.
Topics: Acetylcarnitine; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Oxidative Stress; Resveratrol; Stilbenes | 2007 |
Anti-aging properties of resveratrol: review and report of a potent new antioxidant skin care formulation.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Heart Diseases; Humans; Resveratrol; Sirtuins; Skin Aging; Stilbenes; Wine | 2008 |
4 trial(s) available for resveratrol and Alzheimer Disease
| Article | Year |
|---|---|
Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease.
Topics: Alzheimer Disease; Cognition; Donepezil; Humans; Indans; Piperidines; Resveratrol | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult | 2022 |
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Resveratrol; Stilbenes | 2015 |
Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.
Topics: Activities of Daily Living; Adaptive Immunity; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL5; Cognition Disorders; Cytokines; Double-Blind Method; Encephalitis; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Male; Matrix Metalloproteinase 9; Mental Status Schedule; Peptide Fragments; Resveratrol; Stilbenes; tau Proteins | 2017 |
121 other study(ies) available for resveratrol and Alzheimer Disease
| Article | Year |
|---|---|
Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.
Topics: Algorithms; Alzheimer Disease; Amyloid beta-Peptides; Animals; Bradykinin; Curcumin; Microscopy, Electron; PC12 Cells; Peptide Fragments; Polymers; Rats; Solutions; Spectrophotometry, Ultraviolet; Stilbenes | 2007 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain; Drug Design; Free Radical Scavengers; Humans; In Vitro Techniques; Ligands; Mice; Mice, Transgenic; Phenols; Plaque, Amyloid; Protein Binding; Stereoisomerism; Stilbenes | 2010 |
Protective effect of ε-viniferin on β-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzofurans; Humans; PC12 Cells; Rats; Spectrometry, Mass, Electrospray Ionization; Stilbenes; Vitis | 2011 |
Design, synthesis, and evaluation of resveratrol derivatives as Aß(₁-₄₂) aggregation inhibitors, antioxidants, and neuroprotective agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Reactive Oxygen Species; Resveratrol; Stilbenes; Structure-Activity Relationship | 2012 |
Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cholinesterase Inhibitors; Clioquinol; Drug Design; Humans; Mice; Monoamine Oxidase Inhibitors; Peptide Fragments; Resveratrol; Stilbenes | 2013 |
Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line, Tumor; Copper; Humans; Neuroprotective Agents; Reactive Oxygen Species; Resveratrol; Stilbenes | 2014 |
Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Benzylisoquinolines; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Structure-Activity Relationship | 2014 |
Sulfonamides as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Donepezil; Free Radical Scavengers; Humans; Indans; Molecular Dynamics Simulation; Piperidines; Protein Binding; Sulfonamides | 2015 |
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chelating Agents; Coumarins; Drug Design; Humans; Metals; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Structure, Tertiary; Rats | 2015 |
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Clioquinol; Cognition; Cyclic Nucleotide Phosphodiesterases, Type 4; Inflammation; Ligands; Male; Memory; Models, Molecular; Neurons; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Protein Aggregates; Rats; Rats, Wistar; Resorcinols | 2015 |
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Stilbenes; Structure-Activity Relationship | 2016 |
Ionophoric polyphenols selectively bind Cu(2+), display potent antioxidant and anti-amyloidogenic properties, and are non-toxic toward Tetrahymena thermophila.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Carbon-13 Magnetic Resonance Spectroscopy; Copper; Polyphenols; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Tetrahymena thermophila | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Electrophorus; Horses; Humans; Indans; Indoles; Iron; Kinetics; Melatonin; Molecular Docking Simulation; Peptide Fragments; Piperidines; Protein Multimerization; Rats; Zinc | 2016 |
Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer's disease.
Topics: Allosteric Regulation; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Enzyme Activation; Hemolysis; Humans; Mice; Mice, Transgenic; Molecular Docking Simulation; Neurons; Peptide Fragments; Peptides; Protein Structure, Secondary; Sirtuin 1; Tumor Suppressor Protein p53 | 2017 |
Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Carbolines; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2017 |
Synthesis and biological evaluation of deferiprone-resveratrol hybrids as antioxidants, Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Chelating Agents; Chemistry Techniques, Synthetic; Copper; Deferiprone; Drug Design; Iron; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Structure, Secondary; Pyridones; Resveratrol; Stilbenes; Structure-Activity Relationship | 2017 |
Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Liver; Molecular Targeted Therapy; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Resveratrol; Stilbenes; Tacrine | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Brain Barrier; Chromones; Copper; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Protein Structure, Tertiary; Rats; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; Butyrylcholinesterase; Cell Death; Cholinergic Agents; Cholinesterase Inhibitors; Cinnamates; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; PC12 Cells; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Imines; Ligands; Lipopolysaccharides; Mice; Microglia; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Salicylates; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Proliferation; Drug Design; Hippocampus; Humans; Indoles; Ligands; Memory Disorders; Mice; Quinolines | 2018 |
Design, synthesis, and biological evaluation of compounds with a new scaffold as anti-neuroinflammatory agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Blood-Brain Barrier; Cell Line; Central Nervous System; Drug Design; Humans; Interleukin-1beta; MAP Kinase Signaling System; Nitric Oxide; Phosphorylation; Pyrimidines; Stilbenes; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2018 |
Design, synthesis and evaluation of novel bivalent β-carboline derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase; Carbolines; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Neuroprotective Agents; Okadaic Acid; Peptide Fragments; Protein Structure, Tertiary; Structure-Activity Relationship | 2018 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butylated Hydroxytoluene; Cell Line; Cholinergic Agents; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Mice; Molecular Structure; Neuroprotective Agents; PC12 Cells; Piperidines; Protein Aggregates; Rats; Structure-Activity Relationship | 2018 |
Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzothiazoles; Chelating Agents; Dose-Response Relationship, Drug; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Pyrones; Resveratrol; Structure-Activity Relationship; Sulfonic Acids | 2018 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Prenylation; Rats; Resveratrol; Structure-Activity Relationship | 2019 |
Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Benzimidazoles; Cell Line; Cell Membrane Permeability; Drug Design; Glutathione; Humans; Inflammation; Mice; Neuroprotective Agents; Reactive Oxygen Species; Tetrahydroisoquinolines | 2019 |
Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
Topics: Alzheimer Disease; Animals; Cognition; Drug Design; Enzyme Inhibitors; Glucose; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Oxadiazoles; Reactive Oxygen Species | 2021 |
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship | 2021 |
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetamides; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Biphenyl Compounds; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Oxadiazoles; Picrates; Protein Aggregates; Structure-Activity Relationship | 2022 |
Deer antler extracts reduce amyloid-beta toxicity in a Caenorhabditis elegans model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antlers; Caenorhabditis elegans; Deer; Reactive Oxygen Species; Resveratrol; Superoxide Dismutase; Tissue Extracts | 2022 |
JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cytokines; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Transgenic; Resveratrol; tau Proteins | 2022 |
Resveratrol-Selenium Nanoparticles Alleviate Neuroinflammation and Neurotoxicity in a Rat Model of Alzheimer's Disease by Regulating Sirt1/miRNA-134/GSK3β Expression.
Topics: Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Cholinergic Agents; Glycogen Synthase Kinase 3 beta; Interleukin-1beta; Micronutrients; MicroRNAs; Nanoparticles; Neuroinflammatory Diseases; Neurotoxicity Syndromes; Phosphatidylinositol 3-Kinases; Rats; Resveratrol; Selenium; Sirtuin 1 | 2022 |
Protective effect of pterostilbene in a streptozotocin-induced mouse model of Alzheimer's disease by targeting monoamine oxidase B.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Humans; Inflammation; Interleukin-6; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Neurodegenerative Diseases; NF-kappa B; Reactive Oxygen Species; Resveratrol; Stilbenes; Streptozocin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2022 |
Neuroprotective Effects of Resveratrol by Modifying Cholesterol Metabolism and Aβ Processing in SAMP8 Mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholesterol; Disease Models, Animal; Mice; Neuroprotective Agents; Resveratrol | 2022 |
Bioactivity of hamamelitannin, flavokawain A, and triacetyl resveratrol as natural compounds: Molecular docking study, anticolon cancer, and anti-Alzheimer potentials.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Resveratrol; Structure-Activity Relationship | 2023 |
Modulation of Memory and Neurochemical Changes by Resveratrol and Environmental Enrichment in Rodent Model of Alzheimer's Disease.
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Humans; Male; Mice; Resveratrol; Rodentia | 2022 |
Protective and anti-oxidative effects of curcumin and resveratrol on Aβ-oligomer-induced damage in the SH-SY5Y cell line.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Curcumin; Edaravone; Free Radical Scavengers; Humans; Neuroblastoma; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Reactive Oxygen Species; Resveratrol | 2022 |
Resveratrol-Maltol and Resveratrol-Thiophene Hybrids as Cholinesterase Inhibitors and Antioxidants: Synthesis, Biometal Chelating Capability and Crystal Structure.
Topics: Alzheimer Disease; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Galantamine; Humans; Ligands; Molecular Docking Simulation; Pyrones; Resveratrol; Structure-Activity Relationship; Thiophenes; Trace Elements | 2022 |
Brain targeted peptide-functionalized chitosan nanoparticles for resveratrol delivery: Impact on insulin resistance and gut microbiota in obesity-related Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Chitosan; Gastrointestinal Microbiome; Insulin Resistance; Mice; Nanoparticles; Peptides; Resveratrol | 2023 |
The inhibitory effect and mechanism of small molecules on acetic anhydride-induced BSA acetylation and aggregation.
Topics: Acetic Anhydrides; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloidogenic Proteins; Apigenin; Gallic Acid; Humans; Molecular Docking Simulation; Neurodegenerative Diseases; Protein Aggregates; Protein Processing, Post-Translational; Quercetin; Resveratrol; Vitamin K 3 | 2023 |
Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chitosan; Cognitive Dysfunction; Insulin Resistance; Lipopolysaccharides; Mice; Resveratrol; Selenium; tau Proteins | 2023 |
Resveratrol and Sir2 Reverse Sleep and Memory Defects Induced by Amyloid Precursor Protein.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Drosophila; Drosophila Proteins; Resveratrol; Sirtuin 1; Sleep | 2023 |
Multifunctional Supramolecular Vesicles as Zn
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Mice; Mice, Transgenic; Microglia; Neuroinflammatory Diseases; Resveratrol; Zinc | 2023 |
Intranasal in situ gelling liquid crystal for delivery of resveratrol ameliorates memory and neuroinflammation in Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Liquid Crystals; Neuroinflammatory Diseases; Resveratrol; Scattering, Small Angle; X-Ray Diffraction | 2023 |
Characterization of the molecular interactions between resveratrol derivatives and death-associated protein kinase 1.
Topics: Alzheimer Disease; Apoptosis; Death-Associated Protein Kinases; Humans; Proteins; Resveratrol | 2023 |
Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Hematoxylin; Humans; Molecular Dynamics Simulation; Peptide Fragments; Polyphenols; Resveratrol | 2023 |
Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems.
Topics: Administration, Intravenous; Alzheimer Disease; Animals; Antioxidants; Biological Transport; Biomimetic Materials; Blood-Brain Barrier; Brain; Cell Line; Drug Carriers; Erythrocyte Membrane; Male; Mice; Mice, Inbred ICR; Mitochondria; Nanoparticles; Neurons; Organophosphorus Compounds; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Resveratrol; Tissue Distribution | 2020 |
Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzofurans; Blood-Brain Barrier; Central Nervous System Diseases; Humans; Inflammation; Metabolic Diseases; Neuroprotection; Oxidative Stress; Resveratrol; Stilbenes; tau Proteins | 2020 |
Resveratrol Differently Modulates Group I Metabotropic Glutamate Receptors Depending on Age in SAMP8 Mice.
Topics: Alzheimer Disease; Animals; Mice; Receptors, Metabotropic Glutamate; Resveratrol; Signal Transduction; Synaptic Transmission | 2020 |
Resveratrol-mediated cleavage of amyloid β
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Humans; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Protein Binding; Resveratrol; Tumor Cells, Cultured | 2020 |
Adenosine and Metabotropic Glutamate Receptors Are Present in Blood Serum and Exosomes from SAMP8 Mice: Modulation by Aging and Resveratrol.
Topics: Adenosine; Aging; Alzheimer Disease; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Exosomes; Male; Mice; Receptor, Adenosine A1; Receptors, Adenosine A2; Receptors, Metabotropic Glutamate; Resveratrol | 2020 |
Design, Synthesis and Biological Evaluation of Novel Triazole
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cells, Cultured; Cholinesterase Inhibitors; Curcumin; Humans; Neurons; Neuroprotective Agents; Pharmacokinetics; Reactive Oxygen Species; Resveratrol; Triazoles | 2020 |
A Comparative Study on 5hmC Targeting Regulation of Neurons in AD Mice by Several Natural Compounds.
Topics: 5-Methylcytosine; Alzheimer Disease; Animals; Cell Line, Tumor; Deoxyadenosines; Disease Models, Animal; Humans; Mice; Mice, Mutant Strains; Neurons; Resveratrol | 2020 |
Design and Microwave-Assisted Synthesis of Aza-Resveratrol Analogs with Potent Cholinesterase Inhibition.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Microwaves; Models, Molecular; Molecular Docking Simulation; Resveratrol; Structure-Activity Relationship | 2020 |
Neuroprotective Effects of Chronic Resveratrol Treatment and Exercise Training in the 3xTg-AD Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Exercise; Humans; Mice; Neuroprotective Agents; Physical Conditioning, Animal; Resveratrol | 2020 |
An evaluation of the molecular mode of action of trans-resveratrol in the Porphyromonas gingivalis lipopolysaccharide challenged neuronal cell model.
Topics: Alzheimer Disease; Fallopia japonica; Gene Expression Regulation; Humans; Immunity, Innate; Inflammation; Lipopolysaccharides; Neuroblastoma; Neurons; Oxidative Stress; Periodontitis; Porphyromonas gingivalis; Resveratrol | 2021 |
Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Brain; Cognitive Dysfunction; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Humans; Male; Memory Disorders; Mice; Mice, Transgenic; Neuroprotection; Neuroprotective Agents; Obesity; Proteasome Endopeptidase Complex; Proteolysis; Resveratrol; Ubiquitin | 2021 |
Effects of melatonin and resveratrol on recognition memory and passive avoidance performance in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Behavior, Animal; Disease Models, Animal; Male; Melatonin; Memory Disorders; Mice; Neuroprotective Agents; Recognition, Psychology; Resveratrol | 2021 |
[Network pharmacology-based study of the therapeutic mechanism of resveratrol for Alzheimer's disease].
Topics: Alzheimer Disease; Drugs, Chinese Herbal; Humans; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Resveratrol | 2021 |
Insight into Inhibitory Mechanism of PDE4D by Dietary Polyphenols Using Molecular Dynamics Simulations and Free Energy Calculations.
Topics: Alzheimer Disease; Capsaicin; Catechols; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Fatty Alcohols; Humans; Molecular Dynamics Simulation; Polyphenols; Resveratrol | 2021 |
Unexpected beta-amyloid production by middle doses of resveratrol through stabilization of APP protein and AMPK-mediated inhibition of trypsin-like proteasome activity in a cell model of Alzheimer's disease.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Resveratrol; Up-Regulation | 2021 |
Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antioxidants; Cell Culture Techniques; Humans; Neurites; Neurons; Neuroprotective Agents; Oxidative Stress; Plant Extracts; Prenylation; Resveratrol; Stilbenes | 2017 |
Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.
Topics: Adenylate Kinase; Aging; Alzheimer Disease; Aminoimidazole Carboxamide; Animals; Cannabinoids; Enzyme Activation; Gene Deletion; Glycogen Synthase Kinase 3 beta; Hippocampus; Memory; Memory Disorders; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Phosphorylation; Receptor, Cannabinoid, CB2; Resveratrol; Ribonucleotides; Signal Transduction; tau Proteins | 2018 |
Resveratrol activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced inflammation and oxidative stress.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Cell Survival; Gene Expression Regulation; Humans; Neural Stem Cells; Neuroprotective Agents; Oxidative Stress; Resveratrol; Signal Transduction | 2018 |
Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Embryo, Mammalian; Fibroblasts; HEK293 Cells; Humans; Mice; Microtubule Proteins; Microtubules; Neurofibrillary Tangles; Neurons; Nuclear Proteins; Phosphorylation; Protein Interaction Maps; Protein Phosphatase 2; Proteins; Proteolysis; Resveratrol; tau Proteins; Transcription Factors; Ubiquitin-Protein Ligases | 2017 |
Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Differentiation; Disease Models, Animal; Hippocampus; Humans; Memory; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Transgenic; Neurogenesis; Neurons; Resveratrol; Stilbenes; Umbilical Cord | 2018 |
Dietary Total Prenylflavonoids from the Fruits of Psoralea corylifolia L. Prevents Age-Related Cognitive Deficits and Down-Regulates Alzheimer's Markers in SAMP8 Mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animal Feed; Animals; Biomarkers; Brain; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Flavonoids; Fruit; Glycogen Synthase Kinase 3 beta; Male; Mice; Molecular Structure; Peptide Fragments; Phosphorylation; Protein Aggregates; Psoralea; Resveratrol; Stilbenes; tau Proteins | 2018 |
In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization.
Topics: Administration, Intranasal; Administration, Oral; Alzheimer Disease; Amnesia; Animals; Disease Models, Animal; Drug Carriers; Emulsions; Hydrogels; In Vitro Techniques; Male; Nanostructures; Particle Size; Polysaccharides, Bacterial; Rats; Resveratrol; Scopolamine | 2018 |
Gnetin C, a resveratrol dimer, reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ42-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neuroblastoma; Peptide Fragments; Resveratrol; Stilbenes | 2018 |
Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Hippocampus; Male; Mice, Transgenic; Neurons; Nootropic Agents; Proteostasis; Resveratrol | 2019 |
Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice.
Topics: Acetylation; Alternative Splicing; Alzheimer Disease; Animals; Exons; HEK293 Cells; HeLa Cells; Humans; Mice; Resveratrol; Sirtuin 1; Spatial Memory; tau Proteins | 2018 |
A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: Inhibiting amyloid β aggregation and reactive oxygen species formation properties.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Humans; Nanoparticles; PC12 Cells; Protein Aggregates; Protein Aggregation, Pathological; Rats; Reactive Oxygen Species; Resveratrol; Selenium | 2018 |
Insights into the inhibitory mechanism of a resveratrol and clioquinol hybrid against Aβ
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Dynamics Simulation; Peptide Fragments; Protein Binding; Protein Conformation, beta-Strand; Resveratrol; Small Molecule Libraries | 2019 |
Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; beta-Cyclodextrins; Blood-Brain Barrier; Camphanes; Cell Line, Tumor; Cells, Cultured; Delayed-Action Preparations; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Synergism; Humans; Mice; Nanoconjugates; Oxidation-Reduction; Porosity; Protein Aggregation, Pathological; Reactive Oxygen Species; Resveratrol; Selenium; Specific Pathogen-Free Organisms | 2019 |
Exercise and resveratrol increase fracture resistance in the 3xTg-AD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Exercise Test; Male; Mice; Mice, Transgenic; Protective Agents; Resveratrol; Tibia; Tibial Fractures; Weight-Bearing | 2019 |
Resveratrol Abrogates Hypoxia-Induced Up-Regulation of Exosomal Amyloid-β Partially by Inhibiting CD147.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Basigin; Hippocampus; Hypoxia; Male; Mice, Inbred C57BL; Peptide Fragments; Resveratrol; Transcriptional Activation; Up-Regulation | 2019 |
Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plaque, Amyloid; Presenilin-1; Resveratrol | 2019 |
Effects of Resveratrol on the Mechanisms of Antioxidants and Estrogen in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Estrogens; Glutathione Peroxidase; Heme Oxygenase-1; Male; Malondialdehyde; Mice; NF-E2-Related Factor 2; Oxidative Stress; Resveratrol; Signal Transduction; Superoxide Dismutase | 2019 |
Brain targeting of resveratrol through intranasal lipid vesicles labelled with gold nanoparticles:
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Bioaccumulation; Brain; Gold; Lipids; Male; Metal Nanoparticles; Neuroprotective Agents; Particle Size; Rats; Rats, Wistar; Resveratrol; Tomography, X-Ray Computed | 2019 |
[Resveratrol upregulates the gene and protein expressions of N-methyl-D-aspartate receptor 1 and protein kinase C in the hippocampus in Alzheimer's disease rats].
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Female; Hippocampus; Humans; Protein Kinase C; Random Allocation; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Resveratrol | 2019 |
Role of Resveratrol and Selenium on Oxidative Stress and Expression of Antioxidant and Anti-Aging Genes in Immortalized Lymphocytes from Alzheimer's Disease Patients.
Topics: Aging; Alzheimer Disease; Antioxidants; Cell Line; Gene Expression Regulation; Humans; Lymphocytes; Oxidative Stress; Resveratrol; Selenium | 2019 |
Resveratrol inhibits β-amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Calcium; Cell Survival; Flow Cytometry; Gene Expression Regulation; Homeostasis; L-Lactate Dehydrogenase; Neurodegenerative Diseases; Neurons; PC12 Cells; Peptide Fragments; Rats; Resveratrol; rho-Associated Kinases; Signal Transduction; Sirtuin 1; Stilbenes; Tetrazolium Salts; Thiazoles | 2013 |
Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cerebrum; Dietary Supplements; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Mice; Mice, Transgenic; Mutant Chimeric Proteins; Mutation; Nerve Tissue Proteins; Neurons; Neuropeptides; Neuroprotective Agents; Phosphorylation; Prealbumin; Presenilin-1; Protein Processing, Post-Translational; Recombinant Proteins; Resveratrol; Specific Pathogen-Free Organisms; Stilbenes | 2014 |
Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-κB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AβPP/PS-1 transgenic mouse brain.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Enzyme Inhibitors; Ferric Compounds; Humans; Imaging, Three-Dimensional; Metal Nanoparticles; Mice; Mice, Transgenic; Microglia; Mutation; Neuroprotective Agents; NF-kappa B; Plaque, Amyloid; Presenilin-1; Resveratrol; Stilbenes | 2014 |
Fluorogenic resveratrol-confined graphene oxide for economic and rapid detection of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Fluorescence; Fluorescent Antibody Technique; Graphite; Humans; Mice; Resveratrol; Stilbenes | 2014 |
New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol.
Topics: Absorption, Physiological; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chelating Agents; Clioquinol; Copper; Drug Design; Hydroxyl Radical; Mice; Oxidation-Reduction; Permeability; Protein Aggregates; Resveratrol; Small Molecule Libraries; Spectrophotometry, Ultraviolet; Stilbenes | 2014 |
Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Male; Memory Disorders; Memory, Short-Term; Mice, Transgenic; Neuroprotective Agents; Plaque, Amyloid; Presenilin-1; Recognition, Psychology; Resveratrol; Stilbenes | 2014 |
Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Estradiol; Lipopolysaccharides; Memory; Mice; Motor Activity; Neprilysin; Random Allocation; Resveratrol; Signal Transduction; Stilbenes; Treatment Outcome | 2015 |
ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cholecalciferol; Cognitive Dysfunction; Dietary Supplements; Docosahexaenoic Acids; Fatty Acids, Omega-3; Female; Humans; Inflammation; Macrophages; Male; Mental Status Schedule; Middle Aged; Monocytes; Phagocytosis; Resveratrol; RNA, Messenger; Stilbenes | 2015 |
Resveratrol reduces amyloid-beta (Aβ₁₋₄₂)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagy; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Carrier Proteins; Disease Models, Animal; Endoplasmic Reticulum Stress; Mitochondria; Paralysis; Peptide Fragments; Proteasome Endopeptidase Complex; Proteostasis Deficiencies; Resveratrol; RNA Interference; Stilbenes; Ubiquitins; Unfolded Protein Response | 2016 |
Biological and computational evaluation of resveratrol inhibitors against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cell Death; Cell Line; Dose-Response Relationship, Drug; Mice; Molecular Dynamics Simulation; Molecular Structure; Neurons; Oxidative Stress; Resveratrol; Stilbenes; Structure-Activity Relationship | 2016 |
Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Blood-Brain Barrier; Claudin-5; Disease Models, Animal; Female; Galactose; Glycation End Products, Advanced; Hippocampus; Matrix Metalloproteinase 9; Ovariectomy; Peptide Fragments; Rats; Rats, Wistar; Resveratrol; Stilbenes; Transcription Factor RelA | 2015 |
[Effects of resveratrol on hippocampal astrocytes and expression of TNF-α in Alzheimer's disease model rate].
Topics: Alzheimer Disease; Animals; Astrocytes; Disease Models, Animal; Estradiol; Female; Galactose; Glial Fibrillary Acidic Protein; Hippocampus; Humans; Ovariectomy; Rats; Resveratrol; Stilbenes; Tumor Necrosis Factor-alpha | 2015 |
The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Antioxidants; Aspartic Acid Endopeptidases; Caspase 3; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation; Glycation End Products, Advanced; Heat-Shock Proteins; Humans; Neurons; Neuroprotective Agents; Plaque, Amyloid; Presenilin-1; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Resveratrol; Sirtuin 1; Stilbenes; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Male; Memory Disorders; Mice; Mice, Inbred ICR; Peptide Fragments; Phosphodiesterase 4 Inhibitors; Resveratrol; Signal Transduction; Stilbenes | 2016 |
Live fast, die young.
Topics: Africa; Aging; Alzheimer Disease; Amyloid; Animal Feed; Animal Husbandry; Animals; Animals, Laboratory; Breeding; Caloric Restriction; CRISPR-Cas Systems; Crosses, Genetic; Disease Models, Animal; Female; Fundulidae; Genetic Engineering; Genomics; Iron; Life Cycle Stages; Longevity; Male; Mice; Models, Animal; Neurosciences; Resveratrol; Stilbenes; Time Factors | 2016 |
Superparamagnetic nanoparticle-enhanced MRI of Alzheimer's disease plaques and activated microglia in 3X transgenic mouse brains: Contrast optimization.
Topics: Alleles; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloidogenic Proteins; Animals; Brain; Contrast Media; Disease Models, Animal; Ferric Compounds; Homozygote; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Magnetite Nanoparticles; Metal Nanoparticles; Mice; Mice, Transgenic; Micelles; Microglia; Mutation; Plaque, Amyloid; Resveratrol; Stilbenes | 2017 |
Resveratrol for Alzheimer's disease?
Topics: Adaptive Immunity; Alzheimer Disease; Amyloid beta-Peptides; Humans; Inflammation; Resveratrol | 2017 |
Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Drug Compounding; Drug Delivery Systems; Drug Liberation; Grape Seed Extract; Immunoconjugates; Lipids; Nanoparticles; Particle Size; Permeability; Plant Extracts; Protein Aggregates; Protein Aggregation, Pathological; Resveratrol; Stilbenes; Vitis | 2017 |
Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Electrophorus; Humans; Kinetics; Mannich Bases; Metals; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridoxine; Rats; Resveratrol; Stilbenes | 2017 |
Grapes and human health: a perspective.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Diet; Fruit; Health Promotion; Humans; Resveratrol; Stilbenes; Urinary Bladder Diseases; Vitis | 2008 |
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Ascorbic Acid; Benzothiazoles; Blotting, Western; Brain; Cerebral Ventricles; Cysteine; Dietary Supplements; Female; Glutathione; Hippocampus; Humans; Immunohistochemistry; Male; Mice; Mice, Transgenic; Plaque, Amyloid; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes; tau Proteins; Thiazoles; Transcription Factors; Tumor Suppressor Protein p53 | 2009 |
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Amyloid beta-Peptides; Animals; Autophagy; Calcium; Cytosol; Enzyme Inhibitors; Humans; Lysosomes; Male; Mice; Mice, Transgenic; Neurons; Resveratrol; Signal Transduction; Stilbenes | 2010 |
Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cell Line, Tumor; Coordination Complexes; Humans; Neuroblastoma; Resveratrol; Signal Transduction; Stilbenes | 2011 |
Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Analysis of Variance; Animals; Biological Availability; Brain; Dietary Supplements; Disease Models, Animal; Female; Gas Chromatography-Mass Spectrometry; Gene Expression Regulation; Male; MAP Kinase Kinase 4; Maze Learning; Mice; Neurotransmitter Agents; NF-kappaB-Inducing Kinase; Phosphorylation; PPAR alpha; Protein Serine-Threonine Kinases; Resveratrol; Signal Transduction; Sirtuin 1; Stilbenes; tau Proteins | 2012 |
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Transformed; Cytokines; Disease Models, Animal; Drug Interactions; Humans; I-kappa B Proteins; Inflammation Mediators; Lipopolysaccharides; Male; Mice; Mice, Transgenic; Microglia; NF-KappaB Inhibitor alpha; Presenilin-1; Resveratrol; Signal Transduction; Statistics, Nonparametric; Stilbenes; Time Factors; Toll-Like Receptors; Tumor Necrosis Factor-alpha | 2012 |
A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Cell Engineering; Curcumin; Drug Evaluation, Preclinical; Gene Expression; Genes, Reporter; Green Fluorescent Proteins; Humans; Microscopy, Fluorescence; Models, Biological; Mutation; Nicotiana; Peptide Fragments; Phosphotransferases (Alcohol Group Acceptor); Plant Cells; Protein Binding; Protein Conformation; Protein Folding; Recombinant Fusion Proteins; Resveratrol; Stilbenes | 2012 |
Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Cell Line, Tumor; Diflunisal; Dinitrophenols; Humans; Mutation; Phthalic Acids; Prealbumin; Protein Binding; Resveratrol; Stilbenes | 2012 |
Beneficial effects of lysosome-modulating and other pharmacological and nanocarrier agents on amyloid-beta-treated cells.
Topics: Acetylcarnitine; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Drug Carriers; Endosomes; Humans; Kaempferols; Lactic Acid; Lysosomes; Memantine; Mifepristone; Nanoparticles; Neuroprotective Agents; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Resveratrol; Stilbenes | 2012 |
Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8.
Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Blotting, Western; Caloric Restriction; Cognition; Dietary Supplements; Disease Models, Animal; Enzyme Inhibitors; Immunohistochemistry; Longevity; Mice; Resveratrol; Ribonucleotide Reductases; Stilbenes | 2013 |
Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Catechin; Cell Line; Gene Expression Regulation; Humans; Molecular Structure; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Quercetin; Resveratrol; Stilbenes; Wine | 2005 |
SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Bromodeoxyuridine; Cells, Cultured; Genes, Reporter; Genetic Vectors; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus; Lysine; Microglia; Microscopy, Fluorescence; Models, Biological; Models, Genetic; Neurons; NF-kappa B; Rats; Rats, Sprague-Dawley; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sirtuin 1; Sirtuins; Stilbenes | 2005 |
[Effect of resveratrol on the cognitive ability of Alzheimeros mice].
Topics: Alzheimer Disease; Animals; Antioxidants; Cognition; Female; Galactose; Mice; Ovariectomy; Random Allocation; Resveratrol; Stilbenes | 2006 |
Antioxidative effects of plant polyphenols: from protection of G protein signaling to prevention of age-related pathologies.
Topics: Aged, 80 and over; Aging; Alzheimer Disease; Antioxidants; Curcumin; Female; Flavonoids; Genistein; GTP-Binding Proteins; Humans; Oxidative Stress; Phenols; Plant Preparations; Polyphenols; Resveratrol; Signal Transduction; Stilbenes | 2007 |
SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.
Topics: Acetylation; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Cyclin-Dependent Kinase 5; Disease Models, Animal; Enzyme Activation; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Nerve Degeneration; Rats; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes; Superoxide Dismutase; Superoxide Dismutase-1; Tumor Suppressor Protein p53 | 2007 |